The shares of Retrophin Inc. (NASDAQ:RTRX) has been pegged with a rating of Equal Weight by Barclays in its latest research note that was published on February 25, 2020. The Healthcare company has also assigned a $19 price target. Barclays wasn’t the only research firm that published a report of Retrophin Inc., with other equities research analysts also giving their opinion on the stock. The stock had earned Buy rating from Nomura Markets when it published its report on November 19, 2018. That day the Nomura set price target on the stock to $57. The stock was given Buy rating by Canaccord Genuity in its report released on August 17, 2018, the day when the price target on the stock was placed at 36. JMP Securities was of a view that RTRX is Mkt Outperform in its latest report on November 02, 2015. Deutsche Bank thinks that RTRX is worth Buy rating. This was contained in the firm’s report on June 04, 2015 in which the stock’s price target was also moved to 55.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 1 believe it has the potential for further growth, thus rating it as Hold while 7 advised investors to purchase the stock. The price of the stock the last time has raised by 51.34% from its 52-Week high price while it is -41.72% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 50.07.
The shares of the company added by 13.63% during the trading session on Wednesday, reaching a low of $11.81 while ending the day at $13.59. During the trading session, a total of 831982.0 shares were traded which represents a -108.03% decline from the average session volume which is 399930.0 shares. RTRX had ended its last session trading at $11.96. Retrophin Inc. debt-to-equity ratio currently stands at 0.93, while its quick ratio hovers at 4.40 RTRX 52-week low price stands at $8.98 while its 52-week high price is $23.32.
The company in its last quarterly report recorded -$0.70 earnings per share which is below the predicted by most analysts. The Retrophin Inc. generated 62.44 million in revenue during the last quarter. In the second quarter last year, the firm recorded -$0.85 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -41.43%. Retrophin Inc. has the potential to record -2.74 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Jefferies published a research note on February 18, 2020 where it informed investors and clients that Ardelyx Inc. (NASDAQ:ARDX) is now rated as Buy. Their price target on the stock stands at $11. Citigroup also rated ARDX as Initiated on February 12, 2020, with its price target of $13 suggesting that ARDX could surge by 56.46% from its current share price. Even though the stock has been trading at $5.96/share, analysts expect it to down by -5.03% to reach $13.00/share. It started the day trading at $6.32 and traded between $5.58 and $5.66 throughout the trading session.
A look at its technical shows that ARDX’s 50-day SMA is 6.79 while its 200-day SMA stands at 5.23. The stock has a high of $8.81 for the year while the low is $2.10. The stock, however, witnessed a rise in its short on 03/13/20. Compared to previous close which recorded 3.2 M shorted shares, the short percentage went higher by 9.57%, as 3.51M RTRX shares were shorted. At the moment, only 3.98% of Ardelyx Inc. shares were sold short. The company’s average trading volume currently stands at 847.61K shares, which means that the short-interest ratio is just 3.78 days. Over the past seven days, the company moved, with its shift of 24.67%. Looking further, the stock has dropped -30.47% over the past 90 days while it gained 9.06% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Deerfield Management Company LP bought more ARDX shares, increasing its portfolio by 105.98% during the last quarter. This move now sees The Deerfield Management Company LP purchasing 3,603,843 shares in the last quarter, thus it now holds 7,004,253 shares of ARDX, with a total valuation of $48,469,431. Adage Capital Management LP meanwhile bought more ARDX shares in the recently filed quarter, changing its stake to $39,432,527 worth of shares.
Following these latest developments, around 0.80% of Ardelyx Inc. stocks are owned by institutional investors and hedge funds.